Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov 22;20(23):5867.
doi: 10.3390/ijms20235867.

Osteoporosis in Rheumatic Diseases

Giovanni Adami  1 , Angelo Fassio  1 , Maurizio Rossini  1 , Cristian Caimmi  1 , Alessandro Giollo  1 , Giovanni Orsolini  1 , Ombretta Viapiana  1 , Davide Gatti  1
Affiliations
Review

Osteoporosis in Rheumatic Diseases

Giovanni Adami et al. Int J Mol Sci. .

Abstract

Osteoporosis is a chronic disease characterized by an increased risk of fragility fracture. Patients affected by rheumatic diseases are at greater risk of developing osteoporosis. The purpose of the present review is to discuss the pathogenesis, epidemiology, and treatment of osteoporosis in patients affected by rheumatic diseases with special focus for rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, systemic lupus erythematosus, systemic sclerosis, vasculitides, Sjogren syndrome, and crystal-induced arthritis.

Keywords: arthritis; inflammation; osteoporosis; rheumatic diseases; rheumatology.

PubMed Disclaimer

Conflict of interest statement

Giovanni Adami, Cristian Caimmi, Alessandro Giollo, Giovanni Orsolini, Ombretta Viapiana, Angelo Fassio and Maurizio Rossini declare that they have no conflict of interest. Davide Gatti declares personal fees from Abiogen, Celgene, Eli-Lilly, Pfizer, UCB, the submitted work.

References

    1. Smith E., Hoy D.G., Cross M., Vos T., Naghavi M., Buchbinder R., Woolf A.D., March L. The global burden of other musculoskeletal disorders: Estimates from the Global Burden of Disease 2010 study. Ann. Rheum. Dis. 2014;73:1462–1469. doi: 10.1136/annrheumdis-2013-204680. - DOI - PubMed
    1. Rossini M., Gatti D., Adami S. Involvement of WNT/β-catenin signaling in the treatment of osteoporosis. Calcif. Tissue Int. 2013;93:121–132. doi: 10.1007/s00223-013-9749-z. - DOI - PubMed
    1. Lacey D.L., Boyle W.J., Simonet W.S., Kostenuik P.J., Dougall W.C., Sullivan J.K., San Martin J., Dansey R. Bench to bedside: Elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat. Rev. Drug Discov. 2012;11:401–419. doi: 10.1038/nrd3705. - DOI - PubMed
    1. Saag K.G., Petersen J., Brandi M.L., Karaplis A.C., Lorentzon M., Thomas T., Maddox J., Fan M., Meisner P.D., Grauer A. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N. Engl. J. Med. 2017;377:1417–1427. doi: 10.1056/NEJMoa1708322. - DOI - PubMed
    1. Rodan G.A., Fleisch H.A. Bisphosphonates: Mechanisms of action. J. Clin. Investig. 1996;97:2692–2696. doi: 10.1172/JCI118722. - DOI - PMC - PubMed